SCHEMBL3033845

SCHEMBL3033845

CC(=O)Nc1cccc(S(=O)(=O)O)c1

nearest known ligand 0.58

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PKM P14618 3/20 0.58
ALDH1A1 P00352 3/20 0.58
HSD17B10 Q99714 2/20 0.58
CYP1A2 P05177 1/20 0.58
CASP6 P55212 1/20 0.55
CASR P41180 2/20 0.53
POLB P06746 1/20 0.53
NR4A1 P22736 1/20 0.53
RAB9A P51151 1/20 0.53
LMNA P02545 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
NAPRT Q6XQN6 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL11091187 0.98 PKM (0.57) PKMALDH1A1HSD17B10CYP1A2CASP6
SCHEMBL3022743 0.98 PKM (0.57) PKMALDH1A1HSD17B10CYP1A2CASP6
Nitrogen SCHEMBL6249279 0.97 PKM (0.56) PKMALDH1A1HSD17B10CYP1A2CASP6
SCHEMBL10788098 0.87 LMNA (0.68) PKMALDH1A1HSD17B10CYP1A2POLB
SCHEMBL15461385 0.86 ALDH1A1 (0.58) PKMALDH1A1HSD17B10CYP1A2POLB
SCHEMBL30266262 0.86 ALDH1A1 (0.58) PKMALDH1A1HSD17B10CYP1A2POLB
SCHEMBL11334838 0.85 CA12 (0.65) ALDH1A1CASRPOLBRAB9ALMNA
SCHEMBL7495022 0.84 PKM (0.57) PKMALDH1A1HSD17B10CYP1A2POLB
SCHEMBL7495027 0.84 CA1 (0.69) POLB
SCHEMBL1036779 0.84 PKM (0.57) PKMALDH1A1HSD17B10CYP1A2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103123671-B The target gene Rv2780 for the treatment of tuberculosis inhibitor screening and application HUAZHONG AGRICULTURAL UNIVERSITY (CN) 2015-11-11 CN claimed
CN-103123671-A Target gene Rv0233 screened by antituberculous inhibitor and application UNIV HUAZHONG AGRICULTURAL 2013-05-29 CN claimed
EP-0095177-B1 PROCESS FOR THE PREPARATION OF N-ACETYLAMINO-ARYL-SULPHONIC ACIDS HOECHST AKTIENGESELLSCHAFT (DE) 1985-07-24 EP claimed
JP-4356456-A None JP disclosed
JP-4356455-A None JP disclosed
WO-2023212019-A1 PYRIMIDINONE-CONTAINING 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2023-11-02 WO disclosed
CN-116413231-A Method for detecting trace diazonium salt in azo compound slurry 沈阳化工研究院有限公司 2023-07-11 CN disclosed
US-8419848-B2 Disazo compounds and their use in ink-jet printing FUJIFILM IMAGING COLORANTS LIMITED (GB) 2013-04-16 US disclosed
US-8038781-B2 Ink composition, inkjet recording ink and inkjet recording method FUJIFILM CORPORATION (JP) 2011-10-18 US disclosed
US-20110200800-A1 Disazo Compounds and Their Use in Ink-Jet Printing FUJIFILM CORPORATION (JP) 2011-08-18 US disclosed
US-20100210603-A1 NOVEL SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE TUNG ROGER D 2010-08-19 US disclosed
US-5585397-A VIRICIDES VERTEX PHARMACEUTICALS, INCORPORATED (US) 1996-12-17 US disclosed
EP-0659181-A1 SULFONAMIDE INHIBITORS OF HIV-ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 1995-06-28 EP disclosed
WO-1994005639-A1 SULFONAMIDE INHIBITORS OF HIV-ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 1994-03-17 WO disclosed
EP-0555699-A2 Aromatic compounds substituted by an urethane group and by an amino group BAYER AG (DE) 1993-08-18 EP disclosed
JP-H04356456-A PRODUCTION OF N-ACETYLAMINOARYLSULFONIC ACID CHLORIDE HOECHST AG 1992-12-10 JP disclosed
JP-H04356455-A SOLID, ISOLATED ANHYDROUS N-ACETYLMETANILIC ACID HOECHST AG 1992-12-10 JP disclosed
EP-0095177-B1 PROCESS FOR THE PREPARATION OF N-ACETYLAMINO-ARYL-SULPHONIC ACIDS HOECHST AKTIENGESELLSCHAFT (DE) 1985-07-24 EP disclosed
US-4487725-A Process for the preparation of N-acetylaminoarylsulfonic acids in sulfuric acid as solvent HOECHST AKTIENGESELLSCHAFT (DE) 1984-12-11 US disclosed
EP-0095177-A1 Process for the preparation of N-acetylamino-aryl-sulphonic acids HOECHST AKTIENGESELLSCHAFT (DE) 1983-11-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210603-A1 NOVEL SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE SPINT2, PRSS1, DNPEP PKM 2645/4885ALDH1A1 1532/4885HSD17B10 1297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.